top of page

DISTINCTIVE

seconD- line folfiri aflIbercept in proSpecTIvely stratified, anti-egfr resistaNt, metastatic coloreCTal  cancer patIents with ras validated wild typstatus (distinctive)

AFLIBERCEPT POST ANTI-EGFR IN CCR

· Correlation of early toxicity with efficacy of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type,anti-EGFR resistant, metastatic colorectal cancer patients – an interim analysis of the phase 2 DISTINCTIVE study – a GISCAD trial

Scarica il file  

· Laboratory parameters plus early toxicity to assess prognostic groups in prospectively stratified, RAS wild type, anti-EGFRresistant, metastatic colorectal cancer patients treated with second-line FOLFIRI-aflibercept in the phase 2 DISTINCTIVE trial – a GISCAD study

Scarica il file  

· Circulating pro-angiogenic factors dynamic changes during treatment with FOLFIRI-aflibercept: interim analysis of DISTINCTIVE study - a GISCAD trial

Scarica il file  

· Monocytes to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in metastatic colorectal cancer patients treated with FOLFIRI-aflibercept - a subgroup analysis from the DISTINCTIVE study - a GISCAD trial

Scarica il file  

bottom of page